Deciding when to transition from Phase II to large-scale Phase III clinical trials remains one of the pharmaceutical industry’s most expensive gambles. In the case of rotavirus vaccines, the process is frequently hampered by a lack of clear immune correlates and inconsistent assay methodologies. The Research Optimization & Trial Outcome Recommender (ROTOR) platform seeks to mitigate these variables by synthesizing clinical, immunogenicity, and scientific datasets into a structured decision-support tool.

SK bioscience will lead the development of this framework alongside PATH, Slalom, and SK AX, utilizing its existing rotavirus vaccine data for initial validation. By creating a scalable model, the consortium intends to provide developers in low- and middle-income countries with the analytical infrastructure needed to optimize R&D strategies. CEO Jaeyong Ahn noted that the project signifies a shift toward scientific efficiency, aiming to reduce the trial-and-error cycle that has historically defined vaccine development. This initiative aligns with the company’s broader digital transformation strategy, which already incorporates digital twin technology and AI-assisted experimental design to streamline production timelines and enhance global health accessibility.